Advertisement
Advertisement

CUE

CUE logo

Cue Biopharma, Inc.

26.01
USD
Sponsored
-0.89
-3.31%
Jun 24, 15:59 UTC -4
Closed
exchange

Pre-Market

25.72

-0.29
-1.13%

Cue Biopharma, Inc. Profile

About

Cue Biopharma, Inc. is an immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. Cue Biopharma, Inc. is headquartered in Cambridge, Massachusetts.

Info & Links

CEO

Usman Azam

Headquarters

40 GUEST STREET
BOSTON, MA 02135, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.cuebiopharma.com

Auditor

RSM US LLP

Share holders

91

Employees

29

Cue Biopharma, Inc. Statistics

Valuation Measures

Market Capitalization2

108.02M

Enterprise Value

91.64M

Enterprise Value/EBITDA(ttm)

-4.98

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

1.04

Price to Book(mrq)

0.87

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

100.00%

Operating Margin(ttm)

-96.85%

Profit Margin(ttm)

-884.47%

Return on Equity(ttm)

-165.19%

Return on Invested Capital(ttm)

-281.94%

Return on Assets(ttm)

-77.77%

Income Statement

Revenue(ttm)

32.73M

Revenue Per Share(ttm)

8.09

Gross Profit(ttm)

32.73M

EBITDA(ttm)3

-18.40M

Net Income Available to Common(ttm)

-19.52M

Diluted EPS(ttm)

-0.32

Share Statistics

Beta (5Y Monthly)

1.57

52-Week Change

19.87%

S&P 500 52-Week Change

20.78%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

4.05M

Dividend Yield

0.00%

Float4

95.51M

% Held by Insiders

1.82%

% Held by Institutions

35.04%

Balance Sheet

Total Cash(mrq)

17.44M

Total Cash Per Share(mrq)

4.31

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

2.74%

Quick Ratio(mrq)

2.74%

Book Value Per Share(mrq)

0.27

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.23

Free Cash Flow(ytd)

-21.82M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement